Due to considerations regarding the appropriate therapeutic regimen for these patients.

The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated with chemo-radiation alone.

Originally the study was planned as Part 1A, Part 1B and Part 2. Part 1A was one arm with zalatumumab fixed dose 8 mg/kg. Part 1B was planned as zalutumumab dose-titration and Part 2 adding a comparator. The trial was prematurely closed for enrolment when patients had only been enrolled in Part 1A due to published results showing increased toxicity from induction chemotherapy without any survival benefit.

Inclusion Criteria:

• NSCLC stage IIIA-IIIB
• Performance status 0 or 1 (Zubrod or WHO Scale)

Exclusion Criteria:

• Evidence of metastases either in a separate lobe of the lung, or extra thoracic
• Patients with high risk of radiation pneumonitis and or compromised lung function
• Estimated life expectancy of less than 3 months
• Prior chemotherapy for lung cancer
• Prior radiotherapy to the chest
• Prior surgery with curative intent for lung cancer

Up to 3 months

The trial was prematurely closed. The original protocol contained Part 1A, followed by Part 1B and Part 2. The trial was terminated when 13 patients were enrolled in Part 1A. Scans for efficacy were planned for Part 1B and Part 2.